Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Payables: 2019-2024

Historic Payables for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $8.5 million.

  • Avidity Biosciences' Payables fell 80.60% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 53.03%. This contributed to the annual value of $8.5 million for FY2024, which is 75.36% down from last year.
  • As of FY2024, Avidity Biosciences' Payables stood at $8.5 million, which was down 75.36% from $34.3 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Payables ranged from a high of $34.3 million in FY2023 and a low of $7.7 million during FY2020.
  • Over the past 3 years, Avidity Biosciences' median Payables value was $32.6 million (recorded in 2022), while the average stood at $25.1 million.
  • Per our database at Business Quant, Avidity Biosciences' Payables surged by 235.57% in 2020 and then plummeted by 75.36% in 2024.
  • Avidity Biosciences' Payables (Yearly) stood at $7.7 million in 2020, then spiked by 81.86% to $14.1 million in 2021, then skyrocketed by 131.25% to $32.6 million in 2022, then climbed by 5.43% to $34.3 million in 2023, then plummeted by 75.36% to $8.5 million in 2024.